Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) shares were up 1.2% on Monday . The stock traded as high as $39.25 and last traded at $39.25. Approximately 784 shares traded hands during trading, a decline of 92% from the average daily volume of 10,242 shares. The stock had previously closed at $38.78.
Analyst Ratings Changes
A number of equities research analysts recently commented on CALT shares. Jefferies Financial Group restated a “hold” rating and issued a $39.00 price objective (down previously from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday, May 28th. Stifel Nicolaus restated a “hold” rating and set a $40.00 price objective (down from $55.00) on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday, May 28th. Lifesci Capital downgraded Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 28th. Citigroup reaffirmed a “neutral” rating and issued a $39.00 target price on shares of Calliditas Therapeutics AB (publ) in a research note on Friday, May 31st. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $39.00 target price on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Six investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $35.00.
Read Our Latest Stock Report on CALT
Calliditas Therapeutics AB (publ) Price Performance
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) last announced its quarterly earnings results on Thursday, May 23rd. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.74). Calliditas Therapeutics AB (publ) had a negative return on equity of 160.87% and a negative net margin of 40.19%. The business had revenue of $28.43 million for the quarter, compared to analysts’ expectations of $35.78 million. On average, sell-side analysts forecast that Calliditas Therapeutics AB will post -0.86 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)
A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. bought a new stake in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 980 shares of the company’s stock, valued at approximately $25,000. 2.83% of the stock is currently owned by institutional investors.
About Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.
Further Reading
- Five stocks we like better than Calliditas Therapeutics AB (publ)
- Stock Market Sectors: What Are They and How Many Are There?
- Arm Holdings: Does the 42% Drop Signal an AI Buying Opportunity?
- How to Start Investing in Real Estate
- Texas Roadhouse Stampedes On EPS Beat as Comp Sales Surge 9.3%
- 3 REITs to Buy and Hold for the Long Term
- Why Warren Buffett Just Sold Half His Stake in Apple Stock
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.